“As a result of the partnership, you can expect to see simplified interventional workflows as we enable physicians to deliver ultrasound services in real time, at the point of care,” Shawn St. Pierre, senior director of strategic innovation at Hologic, told HCB News at the time. “This means facilities can offer a more efficient and cost-effective biopsy procedure without sacrificing image quality or accuracy. On a broader level, the partnership allows Hologic to advance its commitment to early detection and help ensure that women around the globe have access to the most accurate breast health solutions.”

In January, Hologic obtained CE Mark in Europe for the Brevera breast biopsy system with CorLumina imaging technology, a real-time breast biopsy and verification system that streamlines the whole biopsy process.

"The Brevera system is a major breakthrough that transforms the breast biopsy procedure as we know it," Jan Verstreken, Hologic's president for EMEA and Canada said in a statement at the time. "Clinicians are now able to image and verify tissue samples in real time in the procedure room, leading to fast procedure times and an improved experience for women, without compromising accuracy or outcomes.”

Back to HCB News

Business Affairs Homepage